Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valsartan: Exporting France's Success

Executive Summary

Novartis' newfound marketing muscle has turned hypertension drug valsartan (Diovan) into a class leader worldwide, with $1.1 billion in sales last year. But the company's experience in France in tailoring its message to individual physicians has proved particularly successful, and provided a model for other countries.

You may also be interested in...



Renewing Novartis

Novartis has unexpectedly re-created itself with a back-to-basics, centrally-driven marketing effort accomplished by an almost entirely new senior marketing group. The transformation has been expensive and the company used a significant portion of the cost savings from the Ciba/Sandoz merger which created Novartis to finance increased marketing and Phase IV clinical development of key current products, as well as larger and more numerous trials for major development candidates, rather than simply to drive short-term earnings increases. The company is now attempting to take the centralization still further into global management. By creating global brands, it feels it can more efficiently capture leading share of voice and thus, at lower cost and with a smaller total sales force, create worldwide brand leaders.

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.

CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales

Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel